Loading clinical trials...
Loading clinical trials...
The goal of this study is to assess dabigatran pharmacokinetics in NVAF subjects with severe renal impairment defined as creatinine clearance between 15 and 30 mL/min calculated by Cockcroft-Gault for...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Boehringer Ingelheim
NCT07575867 · Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation, and more
NCT05009797 · Atrial Fibrillation
NCT07421076 · Paroxysmal Atrial Fibrillation (PAF)
NCT06500988 · Atrial Fibrillation, Behavior
NCT07490808 · Atrial Fibrillation (AF), Acute Kidney Injury
1160.173.002 Boehringer Ingelheim Investigational Site
Hot Springs, Arkansas
1160.173.023 Boehringer Ingelheim Investigational Site
Fremont, California
1160.173.032 Boehringer Ingelheim Investigational Site
Moreno Valley, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions